All In Biotech

Drug Trial Radar · NCT02735421

Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars

Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects

Last checked: Nov 20, 2026Latest source record: Sep 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

May 13, 2016

Primary completion

Jun 5, 2017

Study completion Nov 23, 2017

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Apr 12, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Prevention
Who can join
All sexes, from 16 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multi-centre, randomized, investigator blinded, vehicle controlled trial using intra-individual comparison (right half-face versus left half-face). Participants with each half-face randomized to one of the two following treatments: * Adapalene 0.3 percent (%) - benzoyl peroxide (BPO) 2.5% gel (TactuPump® Forte). * Vehicle gel The main objective of this trial was to evaluate the effect of Adapalene 0.3% - BPO 2.5% (ABPO Forte) gel versus vehicle gel on the risk of formation of atrophic acne scars in moderate to severe acne participants.

Conditions

  • Acne Vulgaris
  • Atrophic Acne Scars

Interventions

  • ABPO Forte GelDrug

    Participants applied Adapalene 0.3% - Benzoyl peroxide (BPO) 2.5% gel (ABPO Forte) topically to the affected areas once daily for 24 weeks in Part 1 and for 48 weeks in Part 2.

  • Vehicle gelDrug

    Participants applied placebo matched to ABPO Forte gel topically to the affected areas once daily for 24 weeks in Part 1 and 48 weeks in Part 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Total Atrophic Acne Scar Count Per Half-faceTime frame: Week 24

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Markham, Ontario, Canada

  • Site not named

    Oakville, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Windsor, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Saint-Jérôme, Quebec, Canada

  • Site not named

    Nantes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.